Form 4: CRISPR CFO Exercises Options, Sells Shares

CRISPR Therapeutics' Chief Financial Officer, Raju Prasad, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Summary

• Raju Prasad, Chief Financial Officer of CRISPR Therapeutics AG (CRSP), reported transactions on January 6, 2026.
• Prasad exercised stock options to acquire a total of 29,700 common shares.
• Specifically, 23,361 shares were acquired at an exercise price of $45.15 per share.
• An additional 6,339 shares were acquired at an exercise price of $44.31 per share.
• Following the option exercises, Prasad sold a total of 29,700 common shares through multiple transactions.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2025.
• 18,933 shares were sold at a weighted average price of $60.1799, with prices ranging from $60.0000 to $60.7300.
• 5,004 shares were sold at a price of $60.00.
• 5,763 shares were sold at a weighted average price of $60.2134, with prices ranging from $60.0000 to $60.4800.
• After these transactions, Prasad beneficially owns 6,767 direct common shares.
• Prasad also holds 76,639 stock options with an exercise price of $45.15 and an expiration date of March 14, 2033, and 7,493 stock options with an exercise price of $44.31.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-planned insider transactions (option exercise and sale) and does not contain information that would significantly alter the company's fundamental outlook or market sentiment. The use of a 10b5-1 plan indicates a structured approach to managing equity.

Positives

• The exercise of stock options and subsequent sale at a higher price indicates a profitable liquidity event for the Chief Financial Officer.
• The transactions were conducted under a Rule 10b5-1 trading plan, which suggests pre-planned activity rather than opportunistic selling based on new, non-public information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived by the market as a lack of confidence, though this is mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance, as it is a report of past insider transactions.

Industry Context

This filing is a routine disclosure of insider trading activity for a biotechnology company. Such transactions are common for executives managing their personal equity holdings, especially when stock options vest and are exercised. The use of a 10b5-1 plan is standard practice to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: Provides transparency regarding the Chief Financial Officer's equity transactions, which were pre-planned and routine.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Form 4, Insider Transaction, Stock Options, Share Sale, CFO, Raju Prasad, 10b5-1 Plan